Picture of BioLine RX logo

BLRX BioLine RX Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for BioLine RX, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-24.4-23-25.4-30-27.1
Depreciation
Non-Cash Items0.678-0.068-2.487.173.32
Unusual Items
Other Non-Cash Items
Changes in Working Capital2.65-1.714.32-1.29-0.54
Change in Accounts Receivable
Change in Payable / Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities-20.5-24.2-22.7-23.2-23.6
Capital Expenditures-4.24-10.2-0.0730-0.097
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-11.719.85.3316.7-38.1
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-15.99.555.2616.7-38.2
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities38.713.119.217.957.7
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash2.64-1.711.8911.5-3.84

Or unlock with your email

Or unlock with your email